| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | LOL; LOXL |
| WB Predicted band size | 63 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human LOXL1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于LOXL1抗体的参考文献示例(注：文献为模拟示例，仅供参考)：
1. **标题**：*LOXL1 Antibody Attenuates Tumor Progression in Ovarian Cancer Models*
**作者**：Smith A, et al.
**摘要**：研究开发了一种靶向LOXL1的单克隆抗体，发现其通过抑制肿瘤微环境中的胶原交联，显著降低卵巢癌小鼠模型的转移和侵袭能力，提示LOXL1抗体可能作为潜在抗癌疗法。
2. **标题**：*Therapeutic Targeting of LOXL1 with a Humanized Antibody in Fibrotic Disorders*
**作者**：Zhang L, et al.
**摘要**：该文献报道了一种人源化LOXL1抗体，在肺纤维化小鼠模型中可阻断LOXL1介导的细胞外基质重塑，减轻纤维化程度，为纤维化疾病的治疗提供了新策略。
3. **标题**：*LOXL1 as a Biomarker in Glaucoma: Validation via Immunohistochemical Analysis*
**作者**：Brown K, et al.
**摘要**：利用LOXL1特异性抗体对青光眼患者眼组织进行免疫组化分析，发现LOXL1在病变区域异常高表达，提示其可作为青光眼早期诊断的生物标志物。
4. **标题**：*Mechanistic Insights into LOXL1 Inhibition by Neutralizing Antibodies in Atherosclerosis*
**作者**：Wang Y, et al.
**摘要**：研究证明中和性LOXL1抗体通过抑制血管壁氧化应激和胶原沉积，减缓动脉粥样硬化斑块形成，揭示了LOXL1在心血管疾病中的病理机制。
如需实际文献，建议通过PubMed或Google Scholar搜索关键词“LOXL1 antibody therapeutic”或“LOXL1 inhibitor”获取最新研究。
Lysyl oxidase-like 1 (LOXL1) is a copper-dependent enzyme belonging to the lysyl oxidase family, which plays a critical role in extracellular matrix (ECM) remodeling by catalyzing the cross-linking of collagen and elastin. Dysregulation of LOXL1 has been implicated in fibrotic diseases, cancer progression, and metastasis, making it a potential therapeutic target. LOXL1 antibodies are designed to specifically inhibit its enzymatic activity or block its interaction with ECM components, thereby attenuating pathological tissue stiffening, tumor invasion, and fibrosis.
Research on LOXL1 antibodies gained momentum due to its association with exfoliation syndrome (XFS), a major risk factor for glaucoma. Genetic variants in LOXL1 are strongly linked to XFS, though disease mechanisms remain unclear. In oncology, LOXL1 overexpression correlates with poor prognosis in cancers like breast and colorectal, driving interest in antibody-based therapies. Early-stage clinical trials explored anti-LOXL1 agents (e.g., simtuzumab) for fibrosis and cancer, but efficacy was limited, highlighting challenges in target validation and patient stratification.
Current efforts focus on optimizing antibody specificity, understanding LOXL1's dual roles in homeostasis vs. disease, and identifying biomarkers for targeted therapy. Despite setbacks, LOXL1 remains a compelling target due to its central role in ECM pathology.
×
